{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:00:15Z","timestamp":1793170815836,"version":"4.5.0"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"\n Importance<\/jats:title>\n Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are known to increase the risk of retained gastric contents. High-quality data are lacking to guide periprocedure management of GLP-1 and GIP agonists.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the risk of clinically significant residual gastric volume (RGV) in patients who continue vs hold 1 dose of weekly or daily GLP-1 and GIP agonists prior to sedation.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This randomized, single-masked clinical trial conducted at 2 large tertiary referral centers in the US included patients undergoing elective upper endoscopy (EGD) who were receiving GLP-1 or GLP-1\/GIP agonists between July 2024 and May 2025. Eligible participants were adults aged 18 years or older, scheduled for EGD with or without colonoscopy, under moderate sedation or monitored anesthesia care, and taking a stable dose of a GLP-1 or GLP-1\/GIP agonist for at least 1 month. Exclusion criteria were prior foregut surgery, achalasia, documented gastroparesis, RGV on previous endoscopy, gastric outlet obstruction, planned general anesthesia, or recent opioid use. Data were analyzed May 2025.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Participants were randomized to either continue their medication or hold 1 dose prior to the procedure.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Clinically significant RGV, a composite of gastric contents that (1) precludes endoscopic examination, (2) requires premature termination or endotracheal intubation, and\/or (3) results in an aspiration event that necessitates extended observation or monitoring, unplanned therapeutics, or hospital admission.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n There were 60 patients (32 holding 1 dose, 28 continuing medication) in the preplanned interim analysis (median [IQR] age, 62.5 [55.5-67.5] years; 30 female [50.0%]). Clinically significant RGV occurred in 3.1% in the hold group vs 25.0% in the continue group (absolute difference, 21.9% [90% CI, 7.0%-36.7%];\n P<\/jats:italic>\n \u2009=\u2009.003). The trial was terminated early as risk exceeded the preestablished O\u2019Brien-Fleming stopping boundary. In the EGD-only subgroup (35 patients), clinically significant RGV occurred in 46.7% in the continue vs 5.0% in the hold groups (absolute difference, 41.7% [90% CI, 17.9%-65.4%];\n P<\/jats:italic>\n \u2009=\u2009.001). In the EGD plus colonoscopy subgroup (25 patients), who were on clear liquids the day prior, no patients had clinically significant RGV.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This randomized clinical trial found that continuing GLP-1 or GIP agonist in the preprocedural period increased clinically significant RGV but did not increase the risk of other adverse events. Clear liquids the day prior to the procedure may mitigate the risk of clinically significant RGV regardless of GLP-1\/GIP use.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT06533527<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamainternmed.2026.0027","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:30:45Z","timestamp":1773675045000},"page":"578","source":"Crossref","is-referenced-by-count":25,"title":["Holding vs Continuing GLP-1\/GIP Agonists Before Upper Endoscopy"],"prefix":"10.1001","volume":"186","author":[{"given":"Akram I.","family":"Ahmad","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Cleveland Clinic Florida, Weston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samita","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Cleveland Clinic Florida, Weston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Ansari","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cleveland Clinic Florida, Weston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem Jamal","family":"Al-Din","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cleveland Clinic Florida, Weston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Almomani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University of Missouri, Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Valencia","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vargo","sequence":"additional","affiliation":[{"name":"Department of Medicine, MetroHealth Medical System, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Siddiki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Cleveland Clinic Florida, Weston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Nicolas","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cleveland Clinic Florida, Weston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaina","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilak","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cleveland Clinic Florida, Weston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10278","key":"ioi260003r1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"ioi260003r2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial.","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"ioi260003r3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity.","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"21","key":"ioi260003r4","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis.","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"ioi260003r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2023.111091","article-title":"Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy.","volume":"87","author":"Silveira","year":"2023","journal-title":"J Clin Anesth"},{"key":"ioi260003r6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-3-030-51089-3","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity.","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"ioi260003r7","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1177\/10600280211055804","article-title":"Impact of glucagon-like peptide-1 receptor agonists (GLP-1RA) on food content during esophagogastroduodenoscopy (EGD).","volume":"56","author":"Stark","year":"2022","journal-title":"Ann Pharmacother"},{"issue":"8","key":"ioi260003r8","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1007\/s12630-023-02440-3","article-title":"Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report.","volume":"70","author":"Klein","year":"2023","journal-title":"Can J Anaesth"},{"issue":"4","key":"ioi260003r10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.cgh.2023.11.002","article-title":"AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: communication.","volume":"22","author":"Hashash","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"ioi260003r11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s00464-024-11263-2","article-title":"Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period.","volume":"39","author":"Kindel","year":"2025","journal-title":"Surg Endosc"},{"issue":"7","key":"ioi260003r12","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1007\/s11695-024-07278-2","article-title":"Safe continuation of glucagon-like peptide 1 receptor agonists at endoscopy: a case series of 57 adults undergoing endoscopic sleeve gastroplasty.","volume":"34","author":"Maselli","year":"2024","journal-title":"Obes Surg"},{"issue":"6","key":"ioi260003r13","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.14309\/ajg.0000000000002777","article-title":"Glucagon-like peptide-1 receptor agonists increase solid gastric residue rates on upper endoscopy especially in patients with complicated diabetes: a case-control study.","volume":"119","author":"Garza","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"26","key":"ioi260003r14","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.3748\/wjg.v30.i26.3221","article-title":"Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study.","volume":"30","author":"Ghazanfar","year":"2024","journal-title":"World J Gastroenterol"},{"issue":"4","key":"ioi260003r15","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.gie.2024.12.019","article-title":"Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis.","volume":"101","author":"Baig","year":"2025","journal-title":"Gastrointest Endosc"},{"issue":"5","key":"ioi260003r16","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.gie.2024.11.024","article-title":"Quality of bowel preparation for colonoscopy in patients on glucagon-like peptide-1 receptor agonists.","volume":"101","author":"Gala","year":"2025","journal-title":"Gastrointest Endosc"},{"issue":"7","key":"ioi260003r17","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.14309\/ajg.0000000000003362","article-title":"Effect of glucagon-like peptide-1 receptor agonists on bowel preparation for colonoscopy: a systematic review and meta-analysis.","volume":"120","author":"Beran","year":"2022","journal-title":"Off J Am Coll Gastroenterol ACG"},{"issue":"2","key":"ioi260003r18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1055\/a-2419-3875","article-title":"Glucagon-like peptide-1 receptor agonists significantly affect the quality of bowel preparation for colonoscopy.","volume":"57","author":"Abu-Freha","year":"2025","journal-title":"Endoscopy"},{"issue":"6","key":"ioi260003r19","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.14309\/ajg.0000000000002564","article-title":"Effect of glucagon-like peptide-1 receptor agonists on bowel preparation for colonoscopy.","volume":"119","author":"Yao","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"ioi260003r9","unstructured":"American Society of Anesthesiologists. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. June 29, 2023. Accessed August 10, 2025. https:\/\/www.asahq.org\/about-asa\/newsroom\/news-releases\/2023\/06\/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2846278\/jamainternal_ahmad_2026_oi_260003_1778792762.62053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:00:19Z","timestamp":1779116419000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2846278"}},"subtitle":["The OCULUS Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2026.0027","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}